UNSPSC 51292102: Levoprotiline

This classification denotes an antidepressant agent with the molecular formula C20H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KYX86D468O, chemically known as 1-(9,10-ethanoanthracen-9(10h)-yl)-3-(methylamino)propan-2-ol but generally known as levoprotiline, which bears US NIH Compound Identifier 53511. European Medicines Agency schedules Levoprotiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08488MIG.

UNSPSC 51292102 Levoprotiline is a Commodity code that does not reflect the work actually being solicited under it in recent state and local procurement. The three most recent opportunities posted under this code involve naloxone and safe drug deactivation systems, direct-to-manufacturer prescription program implementation, and generic multi-source pharmaceuticals and OTC products—none of which are levoprotiline-specific. The code shows a clear tagging mismatch between its nominal scope and current buying activity, suggesting either miscoding at point of entry or a placeholder assignment pending reclassification by procuring entities.

Recent opportunities span Seminole County, Florida (seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB), the Texas Health and Human Services Commission (conducting an RFI for direct-to-manufacturer prescription program capabilities as of April 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (issuing an RFP for generic multi-source pharmaceuticals and OTC products with response deadline of March 26, 2026). The issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing vehicles, indicating broad public-health-sector engagement with pharmaceutical and medical-supply procurement. Geographic spread covers Florida, Texas, Minnesota, and Oregon through the cooperative arrangement. The code shows little relevant recent activity directly aligned to levoprotiline procurement; business development professionals should verify whether opportunities posted here reflect actual demand for this specific pharmaceutical or represent systematic miscoding upstream in state and local procurement systems.